Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice.

Polakowski IJ, Lewis MK, Muthukkaruppan VR, Erdman B, Kubai L, Auerbach R.

Am J Pathol. 1993 Aug;143(2):507-17.


Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin.

Botella-Estrada R, Malet G, Revert F, Dasí F, Crespo A, Sanmartín O, Guillén C, Aliño SF.

Cancer Gene Ther. 2001 Apr;8(4):278-84.


A protein RNase inhibitor (RNasin) expresses anti-angiogenic properties in mice.

Polakowski IJ, Lewis K, Auerbach R.

EXS. 1992;61:428-31. No abstract available.


Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines.

Bastaki M, Nelli EE, Dell'Era P, Rusnati M, Molinari-Tosatti MP, Parolini S, Auerbach R, Ruco LP, Possati L, Presta M.

Arterioscler Thromb Vasc Biol. 1997 Mar;17(3):454-64.


Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.

Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, Polverini PJ.

Cancer Res. 2001 Mar 1;61(5):2183-8.


Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ.

Cancer Res. 1999 Oct 15;59(20):5209-18.


Inhibition of corneal angiogenesis by local application of vasostatin.

Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, Wu PC, Shin SJ, Tai MH.

Mol Vis. 2005 Jan 13;11:28-35.


Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.

Watanabe M, McCormick KL, Volker K, Ortaldo JR, Wigginton JM, Brunda MJ, Wiltrout RH, Fogler WE.

Am J Pathol. 1997 May;150(5):1869-80.


Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS.

Clin Cancer Res. 2008 Mar 1;14(5):1529-39. doi: 10.1158/1078-0432.CCR-07-4126.


The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats.

Shan S, Lockhart AC, Saito WY, Knapp AM, Laderoute KR, Dewhirst MW.

Clin Cancer Res. 2001 Aug;7(8):2590-6.


Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells.

Aoki S, Cho SH, Ono M, Kuwano T, Nakao S, Kuwano M, Nakagawa S, Gao JQ, Mayumi T, Shibuya M, Kobayashi M.

Anticancer Drugs. 2006 Mar;17(3):269-78.


Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties.

Yagi H, Ueda M, Jinno H, Aiura K, Mikami S, Tada H, Seno M, Yamada H, Kitajima M.

Cancer Sci. 2006 Dec;97(12):1315-20. Epub 2006 Oct 9.


Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells.

Ma X, Ottino P, Bazan HE, Bazan NG.

Invest Ophthalmol Vis Sci. 2004 Sep;45(9):2915-21.


A versatile in vivo chamber angiogenesis assay for measuring anti-angiogenic activity in mice.

Kragh M, Hjarnaa PJ, Bramm E, Binderup L.

Oncol Rep. 2004 Feb;11(2):303-7.


Inhibition of inflammatory corneal angiogenesis by TNP-470.

Joussen AM, Beecken WD, Moromizato Y, Schwartz A, Kirchhof B, Poulaki V.

Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2510-6.


cis-hinokiresinol, a norlignan from Anemarrhena asphodeloides, inhibits angiogenic response in vitro and in vivo.

Jeong SJ, Higuchi R, Ono M, Kuwano M, Kim YC, Miyamoto T.

Biol Pharm Bull. 2003 Dec;26(12):1721-4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk